A preliminary report of the efficacy of Debrisan (dextranomer) in the debridement of cutaneous ulcers.
A randomized trial involving 50 patients has demonstrated that a new type of debriding agent, cross-linked dextran beads with the trade name Debrisan (dextranomer, Pharmacia, Inc.), will produce rapid healing of cutaneous ulcers which have been resistant to conventional therapy over the long-term. Evaluation in terms of a number of therapeutic parameters, including rate of healing, dehydration, sterilization, loss of symptoms, and improvement in physiology, is included in this preliminary study.
D000287:Administration, Topical; D000293:Adolescent; D000328:Adult; D000368:Aged; D002648:Child; D002908:Chronic Disease; D005260:Female; D006801:Humans; D007871:Leg Ulcer / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D011134:Polysaccharides / Q000008:administration & dosage / Q000627:therapeutic use*; D012883:Skin Ulcer / Q000188:drug therapy*; D014647:Varicose Ulcer / Q000188:drug therapy
D011134:Polysaccharides